BioNxt Solutions is developing precision therapeutics through sublingual, transdermal, and targeted chemotherapy delivery platforms.
Our technologies improve drug efficiency, reduce side effects, and deliver treatments with greater accuracy across neurology, immunology, and oncology.
Join us in advancing patient care through smarter drug delivery.
Subscribe to our newsletter for the latest breakthroughs, market insights, and updates on BioNxt’s innovative therapies. Plus, receive instant access to our Corporate Presentation to explore our vision, strategy, and pipeline.
With R&D anchored in Germany and strategic partnerships across North America and Europe, we’re focused on advancing high-impact treatments in areas of critical unmet medical need.
Therapeutic Innovation Across Drug Delivery, Oncology & Mental Health
advanced drug delivery systems—including sublingual thin films and transdermal patches—for improved treatment of neurological and chronic diseases; a targeted chemotherapy platform that delivers cytotoxic agents directly to tumors with reduced systemic toxicity; and a proprietary library of engineered psychedelic compounds, developed to support next-generation therapies for neurological, psychiatric, and inflammatory conditions.
Rapid delivery; development and production of active pharmaceutical ingredients.
Our research and technologies are designed to address critical challenges in modern healthcare, with the potential to improve lives on a global scale.
Learn how BioNxt’s products and platforms aim to support patients living with complex conditions – and how our science is helping shape the future of care.
Dec 9, 2025
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your...
Nov 20, 2025
VANCOUVER, BC / ACCESS Newswire / November 20, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased...
Nov 4, 2025
VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor...
Learn more about Bionxt’s innovation to impact strategy and get access to Bionxt investor information.
CSE:BNXT FSE:BXT OTCQB:BNXTF
